More than $2.1M will be invested in advancing pediatric cancer research and children’s cancer care via the Acceleration Initiative Phase II (AI-2), CureSearch Community Impact Awards – Clinical Trials (CCIA-CT) and the CureSearch Community Impact Awards (CCIA).
Acceleration Initiative II (AI-2)
$1.67M awarded to researchers accelerating the delivery of novel therapeutic agents or clinical trial design for pediatric cancer patients.
Two Grant Recipients
Through AI-2, CureSearch for Children’s Cancer and the Rising Tide Foundation for Clinical Cancer Research (RTFCCR) is awarding $1.67M to two leading pediatric cancer researchers. The two researchers chosen were among 23 competitive applicants, and will address a critical challenge in pediatric cancer treatments: accelerating the delivery of novel therapeutic agents or clinical trial design for pediatric patients.
CureSearch Community Impact Awards (CCIA)
$240,000 awarded to those with projects having an impact on new drugs, patient-centered outcomes and community engagement.
Fourteen Grant Recipients
The CCIA is aimed at augmenting institutional support to accelerate and deliver the highest quality care to children with cancer. Of the 14 grant recipients selected, 13 will focus on psycho-social resources or programs for pediatric cancer patients and families, and one will focus on caregiver resources.
CureSearch Community Impact Awards – Clinical Trials (CCIA-CT)
$260,000 awarded to institutions augmenting efforts to administer clinical trials.
Thirteen Grant Recipients
The CCIA – CT awards opportunity is the result of a new partnership with CureSearch for Children’s Cancer and Gateway for Cancer Research (Gateway) and supports US-based hospitals enrolling patients in pilot or early-phase (Phase Zero, I, II) clinical trials within a single hospital or medical institution.
Want more stories like this?
Get emails that matter, when it matters.